Compounds > 1,25(oh)2-16-ene-23-yne-26,27-hexafluoro-19-nor-d3
Page last updated: 2024-11-13
1,25(oh)2-16-ene-23-yne-26,27-hexafluoro-19-nor-d3
Description
The chemical name you provided, **1,25(OH)2-16-ene-23-yne-26,27-hexafluoro-19-nor-D3**, describes a complex and highly modified steroid molecule. Let's break down its components:
* **1,25(OH)2:** This indicates that the molecule has hydroxyl groups (OH) attached at the 1st and 25th carbon positions. This is characteristic of **vitamin D3**, which is essential for calcium absorption and bone health.
* **16-ene:** The presence of a double bond at the 16th carbon position.
* **23-yne:** This denotes a triple bond at the 23rd carbon position.
* **26,27-hexafluoro:** The 26th and 27th carbon positions have six fluorine atoms attached.
* **19-nor:** This indicates that the 19th carbon atom is missing, making it a nor derivative.
* **D3:** This signifies that the molecule is a derivative of vitamin D3, also known as cholecalciferol.
**In summary, this complex molecule is a highly modified vitamin D3 analog with several structural alterations, including double and triple bonds, fluorine substitutions, and a missing carbon atom.**
**Why is it important for research?**
Modified vitamin D3 analogs are extensively researched for their potential therapeutic applications due to their unique properties. They may exhibit:
* **Increased potency:** Certain modifications can enhance the molecule's activity, making it more effective at its target receptors.
* **Improved bioavailability:** Changes in the molecule's structure can improve its absorption and distribution in the body.
* **Longer half-life:** Some modifications can increase the time the molecule stays active in the body, leading to more sustained effects.
* **Selective activity:** Specific modifications can target certain receptors or tissues, potentially minimizing unwanted side effects.
**This particular molecule, with its unusual combination of modifications, could be investigated for its potential in treating various conditions, including:**
* **Bone diseases:** Vitamin D3 is crucial for bone health, and analogs with improved activity could be beneficial for osteoporosis and other bone disorders.
* **Autoimmune diseases:** Vitamin D3 analogs have shown promise in modulating immune responses, potentially making them useful in managing autoimmune conditions like rheumatoid arthritis.
* **Cancer:** Some vitamin D3 analogs have demonstrated anticancer activity, warranting further investigation for their potential as anti-cancer agents.
**It's important to note that this specific molecule's research history and potential applications are not readily available without further information or specific scientific publications.** However, the structural features of this complex molecule suggest its potential for investigation in the context of vitamin D3 research and development.
1,25(OH)2-16-ene-23-yne-26,27-hexafluoro-19-nor-D3: a vitamin D analog; Ro 26-2198 is the (23Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 73014114 |
MeSH ID | M0362721 |
Synonyms (6)
Synonym |
(oh)2-ene-yne-(f)6-d3 |
ro 26-2198 |
1,25(oh)2-16-ene-23-yne-26,27-hexafluoro-19-nor-d3 |
bxl 698 |
bxl 219 |
195527-19-6 |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 13.03 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.82 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |